16D0 Lewis, Nancy L. - Thomas Jefferson University - Thomas Jefferson University
Dr. Lewis

Nancy L. Lewis, MD

Contact Dr. Lewis

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers
  2. Ontario's coloncancercheck: Results from canada's first province-wide colorectal cancer screening program
  3. Colonoscopy quality assurance in Ontario: Systematic review and clinical practice guideline
  4. Improving transition from paediatric to adult cystic fibrosis care: Programme implementation and evaluation
  5. Screening high-risk populations for lung cancer guideline recommendations
  6. A Phase i trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies
  7. A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
  8. A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors
  9. Ma 1302 nagement of plastic bronchitis with topical tissue-type plasminogen activator
  10. Epidemiology of Burkitt's lymphoma in Northwest Province, Cameroon, 2003-2010
  11. Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
  12. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening
  13. Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer
  14. Effective interventions to facilitate the uptake of breast, cervical and colorectal cancer screening: An implementation guideline
  15. What implementation interventions increase cancer screening rates? a systematic review
  16. Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer
  17. Recruiting regional primary care leads for cancer care Ontario
  18. Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma
  19. Phase I pharmacologic and biologic study of ramucirumab (imc-1121b), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2
  20. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers